The terminology of hyperacute rejection (HAR) has become outmoded and confusing due both to advances that have been made in delaying its onset and due to a proliferation of synonyms for the same pathologic process. Until such time as antibody-mediated xenograft rejection can be classified by the type of causative antibody, it is recommended that the term hyperacute rejection be applied to antibody-mediated rejection with classical HAR occurring within 24 h. Delayed HAR is the same pathologic process encountered after 24 h. Recognition of the key role that venous thrombosis plays in the pathogenesis of HAR allows the microscopist to intelligently interpret biopsies from various portions of a transplanted organ according to the pathologic effects of the obstructed venous drainage of the organ. Particularly in the heart, HAR often shows different pathologic features in the inner compared to the outer myocardium. Once xenografting becomes feasible, it will be possible to apply a grading system of HAR in clinical practice.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s1054-8807(01)00097-7 | DOI Listing |
Sci Rep
December 2024
Pharmacology Research Group, Universidad del Valle, Colombia, Cali, 760043.
Vascularized composite allotransplantation (VCA) represents a clinical challenge for transplant therapy, as it involves different tissues with unique immunogenicity. Even when receiving immunosuppressive therapy, they are more vulnerable to severe hypoxia, microvascular damage, and ultimately the rejection or chronic graft dysfunction after transplantation. This study aimed to develop a surgical protocol for VCA of the ear in a porcine biomodel in the absence of immunosuppression, maintaining the in vitro co-culture of the allograft and assessing their relationship with allograft survival.
View Article and Find Full Text PDFTranspl Int
December 2024
Department of Nephrology, Charité Universitätsmedizin Berlin, Berlin, Germany.
Based on promising results obtained in primate models, pioneers in the US have now started to explore the new frontier of genetically-edited pig-to-human transplantation. The recent transition of xenotransplantation into clinical medicine has included transplants in brain-dead subjects and the compassionate use of xenotransplants in living recipients without options for allotransplantation. While the barrier of hyperacute rejection seems to be successfully overcome by gene editing of donor pigs, the occurrence of accelerated rejection could pose significant limitations to the success of the procedure.
View Article and Find Full Text PDFInt J Surg Case Rep
December 2024
Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. Electronic address:
Introduction: Hyperacute rejection leading to hepatic necrosis or intrahepatic bile duct stricture in ABO incompatible living-donor liver transplant (ABO-i LDLT) has been reported many times. With the advent of rituximab, the incidence of these complications has decreased significantly. However, consecutive biliary disruption after ABO-i LDLT has rarely been reported.
View Article and Find Full Text PDFChin Med J (Engl)
October 2024
Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.
Background: The primary limitation to kidney transplantation is organ shortage. Recent progress in gene editing and immunosuppressive regimens has made xenotransplantation with porcine organs a possibility. However, evidence in pig-to-human xenotransplantation remains scarce, and antibody-mediated rejection (AMR) is a major obstacle to clinical applications of xenotransplantation.
View Article and Find Full Text PDFTranspl Int
October 2024
Transregional Collaborative Research Center 127, Walter Brendel Centre of Experimental Medicine, LMU Munich, Munich, Germany.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!